All patients dosed in phase 1 study of cannabinoid receptor 16-Nov-2023 By Liza Laws Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.